Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer
Molecular profiling of tumors from patients plays a crucial role in precision oncology. While tumor tissue-based genomic testing remains the gold standard in clinical management of patients with non-small cell lung cancer, advances in genomic technologies, the analysis of various bodily fluids, main...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2025-07-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://e-trd.org/upload/pdf/trd-2024-0146.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839636184117018624 |
|---|---|
| author | Yuko Oya Ichidai Tanaka Ross A. Soo |
| author_facet | Yuko Oya Ichidai Tanaka Ross A. Soo |
| author_sort | Yuko Oya |
| collection | DOAJ |
| description | Molecular profiling of tumors from patients plays a crucial role in precision oncology. While tumor tissue-based genomic testing remains the gold standard in clinical management of patients with non-small cell lung cancer, advances in genomic technologies, the analysis of various bodily fluids, mainly blood but also saliva, pleural/pericardial effusions, urine, and cerebrospinal fluid is now feasible and readily available. In this review, we will focus on the clinical application of circulating tumor DNA (ctDNA) in patients with non-small cell lung cancer in the setting of early-stage disease, locally advanced disease with attention to the potential of ctDNA in prognostication, risk stratification, minimal residual disease, and in advanced disease, its role in the detection of genomic markers and mechanisms of acquired resistance. The role of ctDNA and liquid biopsies in lung cancer screening will also be discussed. |
| format | Article |
| id | doaj-art-a55f5f90d9ae4be58fd00d0d2a477791 |
| institution | Matheson Library |
| issn | 1738-3536 2005-6184 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
| record_format | Article |
| series | Tuberculosis and Respiratory Diseases |
| spelling | doaj-art-a55f5f90d9ae4be58fd00d0d2a4777912025-07-08T07:13:16ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842025-07-0188344245310.4046/trd.2024.01464942Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung CancerYuko Oya0Ichidai Tanaka1Ross A. Soo2 Department of Respiratory Medicine & Clinical Allergy, Fujita Health University, Toyoake, Japan Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan Department Hematology-Oncology, National University Hospital, National University Cancer Institute, SingaporeMolecular profiling of tumors from patients plays a crucial role in precision oncology. While tumor tissue-based genomic testing remains the gold standard in clinical management of patients with non-small cell lung cancer, advances in genomic technologies, the analysis of various bodily fluids, mainly blood but also saliva, pleural/pericardial effusions, urine, and cerebrospinal fluid is now feasible and readily available. In this review, we will focus on the clinical application of circulating tumor DNA (ctDNA) in patients with non-small cell lung cancer in the setting of early-stage disease, locally advanced disease with attention to the potential of ctDNA in prognostication, risk stratification, minimal residual disease, and in advanced disease, its role in the detection of genomic markers and mechanisms of acquired resistance. The role of ctDNA and liquid biopsies in lung cancer screening will also be discussed.http://e-trd.org/upload/pdf/trd-2024-0146.pdfnon-small cell lungliquid biopsycirculating tumor dnaminimal residual disease |
| spellingShingle | Yuko Oya Ichidai Tanaka Ross A. Soo Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer Tuberculosis and Respiratory Diseases non-small cell lung liquid biopsy circulating tumor dna minimal residual disease |
| title | Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer |
| title_full | Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer |
| title_fullStr | Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer |
| title_full_unstemmed | Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer |
| title_short | Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer |
| title_sort | integration of liquid biopsy for optimal management of non small cell lung cancer |
| topic | non-small cell lung liquid biopsy circulating tumor dna minimal residual disease |
| url | http://e-trd.org/upload/pdf/trd-2024-0146.pdf |
| work_keys_str_mv | AT yukooya integrationofliquidbiopsyforoptimalmanagementofnonsmallcelllungcancer AT ichidaitanaka integrationofliquidbiopsyforoptimalmanagementofnonsmallcelllungcancer AT rossasoo integrationofliquidbiopsyforoptimalmanagementofnonsmallcelllungcancer |